Imagine being able to diagnose Parkinson’s disease before the telltale tremors even begin—a game-changer for millions worldwide. But here’s where it gets controversial: could a simple blood test hold the key to this breakthrough? A groundbreaking study led by researchers at the Miguel Hernández University of Elche (UMH) suggests just that, though it’s not yet ready for clinical use. Their findings, published in Neurotherapeutics (https://doi.org/10.1016/j.neurot.2025.e00762), reveal that genetic analysis of blood samples could offer a non-invasive way to detect Parkinson’s in its earliest stages, long before severe symptoms emerge. And this is the part most people miss: it’s not just about diagnosis—this method could also help monitor disease progression, potentially paving the way for personalized treatments.
Parkinson’s disease affects approximately 12 million people globally, making it the second most common neurodegenerative disorder and a leading cause of neurological disability. The current challenge? Diagnosing it before irreversible damage occurs. Traditionally, diagnosis relies on clinical exams once visible symptoms appear, but by then, neurological harm is often advanced. And this is where the debate heats up: could early detection through blood-based biomarkers revolutionize how we approach this disease?
The UMH team’s method focuses on analyzing peripheral blood mononuclear cells—a type of immune cell. These cells carry genetic information, and certain genes switch on or off in response to disease development. Using advanced sequencing and bioinformatic tools, the researchers identified over 20 genes with altered activity in untreated Parkinson’s patients. Here’s the kicker: these changes aren’t seen in healthy individuals, suggesting they could serve as reliable diagnostic markers. But it doesn’t stop there—these genes also offer clues about the disease’s underlying mechanisms, from inflammation to iron homeostasis.
Among the 22 genes showing differential expression, some are tied to immune responses, fueling the theory that inflammation plays a role in Parkinson’s. Others are linked to molecular transport in the brain and iron regulation—processes already associated with neurotoxicity. Beyond genes, the study uncovered changes in cellular pathways related to survival, inflammation, and cell death. But here’s the question that divides experts: if these biomarkers are so promising, why isn’t this test already in clinics? The answer lies in the need for larger studies to validate these findings.
The exploratory study involved just 23 Parkinson’s patients and 16 healthy controls, yet its results align with independent research from Italy and the U.S. over the past decade. While the sample size is small, the consistency of findings across studies is hard to ignore. And this is where you come in: do you think blood-based biomarkers could transform Parkinson’s diagnosis, or is it too early to tell? Let’s spark a conversation in the comments.
For those eager to dive deeper, the study’s full details are available in Neurotherapeutics (https://doi.org/10.1016/j.neurot.2025.e00762). This article is a republished version of the original materials (https://in.umh-csic.es/en/articulos/whole-transcriptome-analysis-of-peripheral-blood-mononuclear-cells-from-de-novo-and-drug-naive-parkinsons-disease-patients/), edited for clarity and length. For more information, contact the cited source. Our press release publishing policy is available here (https://www.technologynetworks.com/tn/editorial-policies#republishing).
